Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells + BCMA CAR-T cells (The First Affiliated Hospital of Soochow University)
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of the sequential infusion of autologous anti-CD19 and anti-BCMA chimeric antigen receptor (CAR) T-cells. Developed by The First Affiliated Hospital of Soochow University, it is specifically designed to treat refractory immune-mediated platelet transfusion refractoriness (riPTR) in patients with acute leukemia. The dual-targeting approach aims to eliminate both CD19-positive B cells and BCMA-positive plasma cells, which are responsible for producing the alloantibodies that cause rapid clearance of transfused platelets. By depleting these antibody-producing populations, the therapy seeks to restore the efficacy of platelet transfusions and reduce bleeding risks in hematologic patients. It is currently being evaluated in a Phase 1/2 clinical trial (NCT04846439).
- Other names
- Sequential CD19 and BCMA CAR-T cellsanti-CD19 CAR-T cells + anti-BCMA CAR-T cellsSequential infusion of CD19 and BCMA CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CD19 CAR-T cells + BCMA CAR-T cells (The First Affiliated Hospital of Soochow University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells + BCMA CAR-T cells (The First Affiliated Hospital of Soochow University).